Dolutegravir Appears to Lower Human T-Cell Lymphotropic Virus Type 1 (HTLV-1) Proviral Load: The Emerging Rational Approach to Treatment of HTLV-1–Associated Myelopathy
Clinical Infectious Diseases · 20.05.2026 · 82 (5) · e921-e922
DOI: 10.1093/cid/ciag164 ↗Kurz gefasst
Editorial in der Zeitschrift Clinical Infectious Diseases, online erschienen am 09.03.2026. Verfasst von Eric A Meyerowitz. Beteiligte Einrichtung: Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NewYork, USA. Die Arbeit nennt 8 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NewYork, USA.
ORCID-Profile: Eric A Meyerowitz
Zitieren
APA
Meyerowitz, E. A. (2026). Dolutegravir Appears to Lower Human T-Cell Lymphotropic Virus Type 1 (HTLV-1) Proviral Load: The Emerging Rational Approach to Treatment of HTLV-1–Associated Myelopathy. Clinical Infectious Diseases, 82(5), e921-e922. https://doi.org/10.1093/cid/ciag164
Vancouver
Meyerowitz EA. Dolutegravir Appears to Lower Human T-Cell Lymphotropic Virus Type 1 (HTLV-1) Proviral Load: The Emerging Rational Approach to Treatment of HTLV-1–Associated Myelopathy. Clinical Infectious Diseases. 2026;82(5):e921-e922. doi:10.1093/cid/ciag164
BibTeX
@article{Meyerowitz2026,
author = {Meyerowitz, Eric A},
title = {Dolutegravir Appears to Lower Human T-Cell Lymphotropic Virus Type 1 (HTLV-1) Proviral Load: The Emerging Rational Approach to Treatment of HTLV-1–Associated Myelopathy},
journal = {Clinical Infectious Diseases},
year = {2026},
volume = {82},
number = {5},
pages = {e921--e922},
doi = {10.1093/cid/ciag164}
}
EUVIMED